Trials / Completed
CompletedNCT02293018
Pharmacokinetic Study of MTC896 Gel in Subjects With Acne
A Randomized, Single-Blind, Phase 2 Study to Determine the Safety, Tolerability, and Systemic Exposure of 3 Dose Regimens of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Mimetica Pty Limited · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the pharmacokinetic properties of topically applied MTC896 Gel following application of 0.75% (w/w) MTC896 Gel once daily and twice daily and 1.5% (w/w) once daily over 4 weeks in the treatment of acne.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 0.75% (w/w) MTC896 Gel Once Daily | |
| DRUG | 0.75% (w/w) MTC896 Gel Twice Daily | |
| DRUG | 1.5% (w/w) MTC896 Gel Once Daily |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2014-11-18
- Last updated
- 2015-04-17
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02293018. Inclusion in this directory is not an endorsement.